<DOC>
	<DOCNO>NCT02068508</DOCNO>
	<brief_summary>The purpose study investigate safety efficacy long-term treatment pioglitazone ( Actos Tablets ) routine clinical set combination combination insulin product patient type 2 diabetes mellitus respond inadequately use insulin product addition diet therapy exercise therapy .</brief_summary>
	<brief_title>Pioglitazone Tablets Special Drug Use Surveillance `` Combined Use Insulin Products / Long-term Treatment ''</brief_title>
	<detailed_description>This special drug use surveillance long-term use newly co-administered pioglitazone tablet ( Actos Tablets ) patient type 2 diabetes mellitus poorly control blood glucose use insulin product addition diet therapy exercise therapy ; survey design determine safety efficacy long-term use pioglitazone tablet ( Actos Tablets ) routine clinical set combination combination insulin product ( planned sample size , 1000 . ) The usual adult dosage 15 mg pioglitazone administer orally daily breakfast . Dose adjustment make accord gender , age , symptom upper limit 30 mg .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>Patients type 2 diabetes mellitus assume insulin resistance respond inadequately use insulin product addition diet therapy exercise therapy meet follow criterion enrollment . 1 . Patients treated insulin product least 4 week 2 . Patients start Actos Tablets first time start insulin product 3 . Patients likely available 52week observation evaluation start coadministration Actos Tablets Patients contraindication Actos Tables insulin product treatment</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Drug therapy</keyword>
</DOC>